RESUMEN
Urinary bladder endometriosis as a part of deep infiltrating pelvic endometriosis is well known, but isolated bladder involvement is very rare. A 36-year-old woman, who had two cesarean sections, was complaining of dysuria, frequency and burning micturition. MRI showed a tissular mass probably originating from the cervix and suggestive of a sarcoma. Cystoscopy identified a nodular bluish retro trigonal mass, which was completely resected. Histopathological examination was consistent with a bladder endometrioma. The patient had a conservative treatment based on estrogen-progesterone combination. After three months' follow-up, ultrasound and cystoscopy were performed showing no signs of recurrence.
RESUMEN
Paratesticular liposarcomas are relatively common sarcomas in the paratesticular region, however, the myxoid variant is considered very rare. Due to the infrequency of this malignant disease, no standard treatment would be available. Multiple treatments have reported in literature with different results. Herein, we presented a case of paratesticular myxoid liposarcoma in a 67-year-old man originating from the right paratesticular soft tissue.
RESUMEN
Malakoplakia is a rare inflammatory condition that can affect many organ systems, including genitourinary tract, it is associated with impaired immune function. It is characterized by distinctive Michaelis-Gutmann bodies. Very rare cases have been reported to present as a locally advanced renal mass.
RESUMEN
Clear cell adenocarcinoma of the urethra is an extremely rare neoplasm mainly described in women. Anterior pelvic exenteration was the treatment performed in most reported cases. It seems to have poorer prognosis than urothelial carcinomas.
RESUMEN
BACKGROUND: Effective anticoagulation routinely precludes patients from receiving intravenous thrombolysis with recombinant tissue plasminogen activator to reverse severe symptoms of ischemic stroke. We report what we believe to be the first case of ischemic stroke successfully treated with recombinant tissue plasminogen activator after antagonizing dabigatran with the monoclonal antibody idarucizumab, recently approved worldwide. CASE PRESENTATION: A 75-year-old Caucasian man presented to our hospital with severe aphasia and mild hemiparesis. After providing written consent, he received two doses of 2.5 g of idarucizumab over 20 minutes followed by standard protocol in-label recombinant tissue plasminogen activator application. All symptoms resolved within 1 h. CONCLUSIONS: Applying a recombinant tissue plasminogen activator after antagonizing dabigatran with idarucizumab is feasible and easy to manage in an emergency room or stroke unit. Thus, idarucizumab represents a new therapeutic option for patients receiving dabigatran treatment, reestablishing their eligibility for recombinant tissue plasminogen activator thrombolysis.